Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 1/2 1

Status

Terminated 2Completed 2Recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2FED 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Dermatologic 1CNS 1

Conditions

Carcinoma, Hepatocellular 5Leukemia, Myeloid, Acute 3Uveal Melanoma 2Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Leiomyosarcoma 1HER2 Negative Metastatic Breast Cancer 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma 1Advanced Solid Cancers 1Advanced Pancreatic Cancer 1

Interventions

Sorafenib 79pembrolizumab 37Bevacizumab 36Nivolumab 33lenvatinib 30atezolizumab 24durvalumab 17Oxaliplatin 12Ipilimumab 12regorafenib 9Capecitabine 9tremelimumab 8Injections 8Doxorubicin 8tislelizumab 7sintilimab 7Fluorouracil 7cabozantinib 6budigalimab 6brivanib 6Ramucirumab 6toripalimab 5Gemcitabine 5Everolimus 5Cyclophosphamide 5ADI PEG20 5fludarabine 4Sunitinib 4Leucovorin 4E-7386 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Hepatocellular × ADI PEG20 × Clear all
NCT05317819 2025-12-18

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

Polaris Group

Phase 3 Recruiting
300 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT02102022 2022-04-25

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

Polaris Group

Phase 1/2 Terminated
140 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT02029690 2020-09-25

TRAP

Polaris Group

Phase 1 Terminated
85 enrolled
CNSDermatologicGastrointestinal

Uveal Melanoma, Carcinoma, Glioma, Carcinoma, Hepatocellular

NCT01287585 2019-09-06

ADI-PEG 20

Polaris Group

Phase 3 Completed
636 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT02101593 2016-03-04

Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer

Polaris Group

Phase 1 Completed
8 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡